The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors
Abstract
Background: Activation of the KIT receptor tyrosine kinase is associated with the development of canine mast cell tumors (MCT). Hypothesis/Objective: To evaluate the efficacy of masitinib, a potent and selective inhibitor of KIT, in the treatment of canine MCT. Animals: Two hundred and two client-owned dogs with nonmetastatic recurrent or nonresectable grade II or III MCT. Methods: Double-blind, randomized, placebo-controlled phase III clinical trial. Dogs were administered masitinib (12.5 mg/kg/d PO) or a placebo. Time-to-tumor progression (TTP), overall survival, objective response at 6 months, and toxicity were assessed. Resulsts: Masitinib increased overall TTP compared with placebo from 75 to 118 days (P= .038). This effect was more pronounced when masitinib was used as first-line therapy, with an increase in the median TTP from 75 to 253 days (P= .001) and regardless of whether the tumors expressed mutant (83 versus not reached [P= .009]) or wild-type KIT (66 versus 253 [P= .008]). Masitinib was generally well tolerated, with mild (grade I) or moderate (grade II) diarrhea or vomiting as the most common adverse events. Conclusions and Clinical Importance: Masitinib is safe and effective at delaying tumor progression in dogs presenting with recurrent or nonresectable grade II or III nonmetastatic MCT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity
Hulzinga, J. D., Thuneberg, L., Klüppel, M., Malysz, J., Mikkelsen, H. B., & Bernstein, A. (1995) · Nature · doi:10.1038/373347a0 · Cited by 1,400
Canine Cutaneous Mast Cell Tumor: Morphologic Grading and Survival Time in 83 Dogs
Patnaik, A. K., Ehler, W. J., & MacEwen, E. G. (1984) · Veterinary Pathology · doi:10.1177/030098588402100503 · Cited by 843
Qiu, F. H., Ray, P., Brown, K., Barker, P. E., Jhanwar, S., Ruddle, F. H., & Besmer, P. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02907.x · Cited by 697
Requirement of c-kit for development of intestinal pacemaker system
Maeda, H., Yamagata, A., Nishikawa, S., Yoshinaga, K., Kobayashi, S., Nishi, K., & Nishikawa, S.-I. (1992) · Development · doi:10.1242/dev.116.2.369 · Cited by 697
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT
Dubreuil, P., Letard, S., Ciufolini, M., Gros, L., Humbert, M., Castéran, N., Borge, L., Hajem, B., Lermet, A., Sippl, W., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007258 · Cited by 421
Self-citationLondon, C. A., Hannah, A. L., Zadovoskaya, R., Chien, M. B., Kollias-Baker, C., Rosenberg, M. P., Downing, S., Post, G. S., Boucher, J. F., Shenoy, N. R., et al. (2003) · PubMed · Cited by 280
(2004) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5810.2004.0053b.x · Cited by 240
Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit
Akin, C., Brockow, K., D'Ambrosio, C., Kirshenbaum, A. S., Ma, Y., Longley, B. J., & Metcalfe, D. D. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00112-7 · Cited by 224
Cited by
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT
Dubreuil, P., Letard, S., Ciufolini, M., Gros, L., Humbert, M., Castéran, N., Borge, L., Hajem, B., Lermet, A., Sippl, W., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007258 · Cited by 421
Self-citationEuropean consensus document on mast cell tumours in dogs and cats
Blackwood, L., Murphy, S., Buracco, P., De Vos, J. P., De Fornel‐Thibaud, P., Hirschberger, J., Kessler, M., Pastor, J., Ponce, F., Savary-Bataille, K., et al. (2012) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2012.00341.x · Cited by 268
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis
Ustun, C., DeRemer, D. L., & Akin, C. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.05.006 · Cited by 102
Enhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89
A structural analysis of the FDA green book-approved veterinary drugs and roles in human medicine
Scott, K. A., Qureshi, M. H., Cox, P. B., Marshall, C. M., Bellaire, B. C., Wilcox, M., Stuart, B. A. R., & Njardarson, J. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01502 · Cited by 56
Metadata
- Authors
- Hahn, K. A., Oglivie, G., Rusk, T., Devauchelle, P., Leblanc, A., Legendre, A., Powers, B., Leventhal, P. S., Kinet, J.-P., Palmerini, F., Dubreuil, P., Moussy, A., & Hermine, O.
- Venue
- Journal of Veterinary Internal Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-11-01
- Volume
- 22
- Issue
- 6
- Pages
- 1301-1309
- ISSN
- 0891-6640 (ISSN-L)
- 1939-1676
- OpenAlex
- W2024324841
- Cited by
- 289
- References
- 24
- FWCI
- 13.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors. https://app.cochat.ai/papers/10.1111/j.1939-1676.2008.0190.x
- The paper
- Hahn, K. A., Oglivie, G., Rusk, T., Devauchelle, P., Leblanc, A., Legendre, A., Powers, B., Leventhal, P. S., Kinet, J.-P., Palmerini, F., Dubreuil, P., Moussy, A., & Hermine, O. (2008). Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/j.1939-1676.2008.0190.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.